BENIGN BREAST DISEASE AND THE RISK OF BREAST CANCER IN THE NEXT 15 YEARS

Authors

  • Demetra SOCOLOV University of Medicine and Pharmacy “Grigore T. Popa” - Iasi
  • Ivona ANGHELACHE LUPASCU Cuza Vodă” Obstetrics and Gynecology Clinical Hospital of Iaşi
  • C. ILEA University of Medicine and Pharmacy “Grigore T. Popa” - Iasi
  • R. SOCOLOV University of Medicine and Pharmacy “Grigore T. Popa” - Iasi
  • A. CARAULEANU University of Medicine and Pharmacy “Grigore T. Popa” - Iasi

Keywords:

FIBROCYSTIC MASTOSIS, BREAST CANCER, BREAST SCREENING, ATYPICAL HY-PERPLASIA

Abstract

Aim: Fibrocystic mastosis (FCM) is defined by the totality of dystrophic changes of the mammary tissue, the grouping in the form of fibrosis of epithelial, cystic, metaplastic and hyperplastic alterations. A very good estimation of the cancer risk is related specifically to the microscopic aspect. Other factors, the family history as well as the presence of an inherited gene determining the increase in the risk of breast cancer are also considered. But, if a woman known with fibrocystic mastosis has not undergone any biopsy, then it is impossible to calculate the specific individual risk of developing cancer. Material and methods: The data collected as a study material and considered refer to: the total number of cases investigated and diagnosed with fibrocystic mastosis, the annual distribution of this disease cases, the distribution of the cases according to age groups, admission reasons, clinical examination, personal pathologic history clinically significant for the basic disease (the main diagnosis), the family medical history significant for the basic disease, the anatomopathological diagnosis. Results: Between 2004 and 2006, at “Cuza Vodă” Obstetrics and Gynecology Hospital of Iaşi, a maximum number of cases is noticed in 2006, when there were 147 cases, and the lowest number of cases was in 2005. There was high frequency of the anatomopathological examinations that highlighted the presence of fibrocystic lesions (both proliferative and non-proliferative), and the second most often diagnosis is fibroadenoma. Though fibrocystic mastosis is not clearly defined, it is still admitted that in order to support this diagnosis it is first compulsory to exclude malignant tumours. Conclusions: Only in 5% of the women with fibrocystic mastosis cellular changes can be revealed in the form of atypical hyperplasia, which are a risk factor for cancer. The lesion that delimits cancer from non-cancer is ductal carcinoma in situ. An incidence of over 20% is present in the countries that use mammographic screening programmes, mammographic surveillance programmes and programmes for the guided localization of nonpalpable lesions of the mammary gland.

Author Biographies

  • Demetra SOCOLOV, University of Medicine and Pharmacy “Grigore T. Popa” - Iasi

    Department of Mother and Child Medicine

  • Ivona ANGHELACHE LUPASCU, Cuza Vodă” Obstetrics and Gynecology Clinical Hospital of Iaşi

    1st Clinic of Obstetrics and Gynecology

  • C. ILEA, University of Medicine and Pharmacy “Grigore T. Popa” - Iasi

    Department of Mother and Child Medicine

  • R. SOCOLOV, University of Medicine and Pharmacy “Grigore T. Popa” - Iasi

    Department of Mother and Child Medicine

  • A. CARAULEANU, University of Medicine and Pharmacy “Grigore T. Popa” - Iasi

    Department of Mother and Child Medicine

References

1. Anlauf M, Nicklaus S, Rode G, Jackel C, Neumann K, Kalbfleisch H, Muhlberger G. Clinical expe-rience with percutaneus large-core needle biopsies of the breast and evaluation of cytopathological and histopathological results. Zentralbl Gynakol. 2003; 125(9): 353-361.
2. Popârlan T, Muscă S. Rolul factorilor de prognostic ai cancerului mamar în evaluarea supravieţuirii. Rev Med Chir Soc Med Nat Iaşi 2010; 114(1): 147-151.
3. Georgescu R, Coros MF, Stolnicu S, Podeanu D, Sorlea S, Rosca A, Copotoiu C. Factori prognostici în cancerul mamar. Rev Med Chir Soc Med Nat Iaşi 2012; 116(1): 262-267.
4. Chinyama CN. Benign Breast Diseases-Radiology-Pathology-Risk Assessment. Springer-Berlin, Heidelberg, New York, London 2004.
5. Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. New Engl J Med 1985; 312:146-151.
6. Ivan A. Tratat de epidemiologie a bolilor transmisibile. Editura Polirom, Iaşi, 2002.
7. Haagensen C.D. Diseases of the breast, 3rd Ed. Philadelphia P.A. Saunders 1986: 125-135.
8. Lefranc JP, TranBaloc P, Allier-Pinto S, Balladur A, Blonden J. Les mastopathies benignes. Encycl. Med Chir (Paris-France), Gynecologie. 840 A10, 3-1990, 10.
9. McFarlane ME. Benign breast diseases in an Afro-Caribbean population. East Afr Med J 2001; 78(7): 358-359.
10. Nielsen M, Christensen J, Andersen J. Radial scars in women with breast cancer. Cancer 1987; 59: 1019-1025.
11. Niţescu V. Obstetrică şi ginecologie în practica medicului de familie. Ed. Didactică şi Pedagogică, Bucureşti, 2002.
12. Wellings S.R., Jensen H.M., Marcum R.S. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Nat Cancer Inst 1975; 55(2): 231-273.
13. Yon J.K. et al. Focal fibrosis of the breast diagnosed by a sonographically guided core biopsy of non-palpable lesions. J Ultrasound Med 2005; 24: 1377-1384.

Published

2015-03-31